Latest News
-
Thursday - February 28, 2013
New products create optimism for the future
Bayer: continuing growth momentum
Group targets achieved in 2012 – sales and earnings before special items increase in all subgroups / Sales increase by 8.8 percent to EUR 39,760 million / EBIT EUR 3,960 million (minus 4.6 percent) – Net income EUR 2,446 million (minus 1.0 percent) / Further accounting measures for legal claims / EBITDA before special items rises by 8.8 percent to EUR 8,284 million / Core earnings per share improve by 10.8 percent to EUR 5.35 / Encouraging growth in the emerging markets / Steady progress with innovation pipeline strengthens life-science businesses / Forecast for anniversary year 2013: continuing record development » more
-
Thursday - February 28, 2013
Not intended for U.S. and UK media - Diabetes self-management
More accurate blood glucose meters can reduce cost burden in health care
A new health economic analysis confirms Bayer HealthCare’s approach on developing advanced blood glucose monitoring systems » more
-
Tuesday - February 26, 2013
Bayer proposes dividend increase to EUR 1.90 per share for 2012
Payout up 15 percent to EUR 1,571 million » more
-
Tuesday - February 26, 2013
Not Intended for U.S. and U.K. Media
Bayer’s Regorafenib Granted Priority Review in Japan for the Treatment of Patients with Gastrointestinal Stromal Tumors » more
-
Monday - February 25, 2013
Not intended for U.S. and UK media
Bayer’s Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Gastrointestinal Stromal Tumors
Stivarga shown in a pivotal Phase III trial to significantly improve progression-free survival in patients with gastrointestinal stromal tumors (GIST) whose disease had progressed after previous treatments » more
-
Friday - February 22, 2013
New award from the Bayer Science & Education Foundation:
Bayer Thrombosis Research Award 2013 for Dr. Krystin Krauel
Research scientist at Ernst-Moritz-Arndt University Greifswald honored for her work in the field of antibacterial host defenses » more
-
Thursday - February 21, 2013
Bayer MaterialScience introduces new applications for ViviTouch™ at Mobile World Congress
Introducing HD feel to mobile games on a smartphone and tablet
New sensory experience for mobile gaming devices / Headphones with intense, live sound experience » more
-
Thursday - February 21, 2013
New technology from Bayer MaterialScience for consumer electronics:
Mobile games now give HD haptic feedback
ViviTouch™ adds a new sensory dimension to tablet PCs and smartphones / Headphones provide an intense, live sound experience » more
-
Tuesday - February 19, 2013
Bayer MaterialScience develops crosslinker for the gentle coating of textiles
Advantageous applications also possible in glass and automotive OEM coating » more
-
Tuesday - February 19, 2013
Not intended for U.S. and UK Media
Bayer and Regeneron Initiate Phase III Trial of VEGF Trap-Eye (Aflibercept) for the Treatment of Diabetic Macular Edema in Asia and Russia » more
-
Monday - February 18, 2013
New polycarbodiimide crosslinker supports long pot life
Innovative adhesive technology for films and textile fabrics » more
-
Wednesday - February 13, 2013
Not intended for U.S. and UK Media - Castration-Resistant Prostate Cancer with Bone Metastases:
Radium-223 Dichloride Granted Priority Review by U.S. FDA » more
-
Monday - February 11, 2013
Not intended for U.S. and UK media
Bayer’s Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension Submitted For Regulatory Approval in the U.S. and EU
Riociguat is the first drug that has consistently demonstrated efficacy in two life-threatening PH indications – chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) » more
-
Thursday - February 7, 2013
European Innovative Medicines Initiative (IMI):
Bayer supports innovative drug discovery in Europe
Bayer HealthCare to coordinate international consortium “European Lead Factory” aiming at jointly discovering new medicines » more
-
Wednesday - February 6, 2013
Bayer CropScience at the Fruit Logistica 2013 in Berlin:
Food Chain Partnerships continue to grow worldwide » more
-
Wednesday - February 6, 2013
Bayer MaterialScience at the European Coatings Show 2013
“Leading in Polyurethanes” » more
-
Tuesday - February 5, 2013
Not intended for U.S. and UK Media
Xarelto® to be Studied with Factor Xa Inhibitor Antidote
Bayer and Janssen announce clinical collaboration agreement with Portola » more
-
Tuesday - February 5, 2013
Hands-on science for all:
World tour to mark 150 Years of Bayer
From São Paulo to Shanghai: Bayer AG sends interactive exhibition around the world » more
-
Friday - February 1, 2013
Not intended for U.S. and UK media - IMCAS Congress 2013
Positive results of Phase-III trials suggest that ATX-101 is effective as a non-surgical treatment for the reduction of unwanted submental fat » more
-
Thursday - January 31, 2013
Is Europe heading for a set-back in agriculture?
Bayer CropScience strongly disagrees with proposal by EU Commission
Company asks EU Member States to apply proportionality principles » more
Copyright @ Bayer AG